Phase-amplitude coupled persistent theta and gamma oscillations in rat primary motor cortex in vitro

Nicholas W. Johnson a, Mazhar Özkan b, Adrian P. Burgess a, Emma J. Prokie a, Keith A. Wafford c, Michael J. O’Neill c, Stuart D. Greenhill a, Ian M. Stanford a, Gavin L. Woodhall a, *  

a Aston Brain Centre, Aston University, School of Life and Health Sciences, Birmingham, B4 7ET, United Kingdom  
b Department of Anatomy, School of Medicine, Marmara University, Istanbul, Turkey  
c Neuroscience Division, Eli Lilly & Co. Ltd., Windlesham, GU20 6PH, United Kingdom

ARTICLE INFO

Article history:
Received 15 September 2016
Received in revised form 3 April 2017
Accepted 6 April 2017
Available online 8 April 2017

Keywords:
Neuronal network oscillations  
M1  
Theta  
Gamma  
Phase amplitude coupling

ABSTRACT

In vivo, theta (4–7 Hz) and gamma (30–80 Hz) neuronal network oscillations are known to coexist and display phase-amplitude coupling (PAC). However, in vitro, these oscillations have for many years been studied in isolation. Using an improved brain slice preparation technique we have, using co-application of carbachol (10 μM) and kainic acid (150 nM), elicited simultaneous theta (6.6 ± 0.1 Hz) and gamma (36.6 ± 0.4 Hz) oscillations in rodent primary motor cortex (M1). Each oscillation showed greatest power in layer V. Using a variety of time series analyses we detected significant cross-frequency coupling in 74% of slice preparations.

Differences were observed in the pharmacological profile of each oscillation. Thus, gamma oscillations were reduced by the GABA_A receptor antagonists, gabazine (250 nM and 2 μM), and picrotoxin (50 μM) and augmented by AMPA receptor antagonism with SYM2206 (20 μM). In contrast, theta oscillatory power was increased by gabazine, picrotoxin and SYM2206. GABA_A receptor blockade with CGP55845 (5 μM) increased both theta and gamma power, and similar effects were seen with diazepam, zolpidem, MK801 and a series of metabotropic glutamate receptor antagonists. Oscillatory activity at both frequencies was reduced by the gap junction blocker carbenoxolone (200 μM) and by atropine (5 μM).

These data show theta and gamma oscillations in layer V of rat M1 in vitro are cross-frequency coupled, and are mechanistically distinct. The development of an in vitro model of phase-amplitude coupled oscillations will facilitate further mechanistic investigation of the generation and modulation of coupled activity in mammalian cortex.

© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Gamma oscillations (30–80 Hz) play a role in attentive states such as sensory perception (Engel and Singer, 2001; Gray et al., 1989; Gray, 1994; Singer and Gray, 1995), memory processing (Chrobak and Buzsáki, 1998; Lisman and Idiart, 1995) and movement execution (Brown et al., 1998; Cheyne et al., 2008; Muthukumaraswamy, 2010; Pfurtscheller et al., 2003). Extensively studied both in vivo and in vitro, gamma oscillations appear to be an emergent property of reciprocally connected inhibitory interneuronal network and pyramidal cells. Whilst excitatory postsynaptic potentials, shunting inhibition and gap junctions play a role in the generation of synchronous activity, the main determinant of the oscillatory frequency is the time constant of decay of interneuronal postsynaptic potentials (Fisahn et al., 1998; Traub et al., 1996, 1999; Wang and Buzsáki, 1996; Whittington et al., 1995).

Theta oscillations (4–7 Hz) are associated with hippocampal and limbic regions involved in exploration, spatial navigation (Cacucci et al., 2004; O’Keefe and Recce, 1993) and spatial and working memory (Buzsáki and Moser, 2013; Cashdollar et al., 2009). During exploration, network oscillations at gamma and...
theta frequency are often co-generated (Bragin et al., 1995) with theta being temporally nested with gamma rhythm (Fisahn et al., 1998; Sirotat al., 2008). Due to conduction delays, low frequency oscillations are able to prefentially synchronise networks over long distances while faster oscillations are thought to synchronise activity in more local networks. Thus, the amplitude of the gamma frequency oscillation is enhanced in phase with the theta cycle due to neuron recruitment. This phenomenon, known as cross-frequency coupling (CFC; Canolty et al., 2006), aids interneuronal network communication and processing such that communications arriving out of phase may be ignored while information in phase may be treated preferentially. In this way, theta may serve to act as a global temporal coordinator of local network activity (Sirotat al., 2008), and theta-gamma coupling has been shown to be essential for structuring of motor-related activity in rodent M1 (Igarashi et al., 2013).

An understanding of the fundamental mechanisms involved in the generation of neuronal network theta and gamma oscillations has arisen from in vitro studies using stimulus-based and/or pharmacological approaches to induce activity, which may then be characterised using a combination of electrophysiology and neuropharmacology. Thus, transient (lasting milliseconds to seconds) gamma oscillations have been evoked by tetanic electrical stimulation (Traub et al., 1996; Whittington et al., 1997) whilst persistent (lasting hours) gamma oscillations have been generated by application of kainic acid (KA) and/or carbachol (CCh) (Buhl et al., 1998; Cunningham et al., 2003; Dickson et al., 2000; Fisahn et al., 1998) or group 1 metabotropic glutamate receptor (mGluR) activation (Fisahn et al., 1998; Pálhalmi et al., 2004; Whittington et al., 1995). Furthermore, theta rhythms can be generated by the addition of GABA_B receptor antagonists along with CCh (Konopacki et al., 2004; Whittington et al., 1995). Additionally, theta rhythms can also be generated by electrical coupling through gap junctions (Bocian et al., 2000; Gillies et al., 2002). In addition, rhythm generation is also enhanced by electrical coupling through gap junctions (Rocian et al., 2011; Kopell and Ermentrout, 2004; Szabédis et al., 2001; Tamas et al., 2000) which are prevalent between interneurons (Beierlein et al., 2000; Deans et al., 2001; Galarreta and Hestrin, 1999).

Previous studies in M1 in vitro have shown that co-application of KA and CCh elicits beta oscillations (Lacey et al., 2014; Yamawaki et al., 2008) while electrical stimulation at different frequencies evoked theta, beta and gamma activity revealing the ability for M1 to promote multiple rhythms of different frequencies (Yamawaki et al., 2008). In this study, using an improved brain slice preparation based on a protocol utilising a number of neuroprotective agents, we have been able to generate pharmacoologically-induced persistent theta and gamma oscillations in M1 that demonstrates CFC. Furthermore, pharmacoological investigations reveal that theta activity is generated and modulated by distinct receptor types, with contributions from both intrinsic and synaptic mechanisms.

2. Materials and methods

2.1. In vitro slice preparation

Sagittal brain slices (450 µm thick) containing M1 were prepared from male Wistar rats (20–30 days of age, 50–150 g). All animal procedures were performed in accordance with the Aston University policy and in accordance with the Animals (Scientific Procedures) Act UK 1986 and European Communities Directive 2010/63/EU. Animals were first anaesthetised using isoflurane (2% in O2) until no heartbeat was detected and then transcardially perfused with ice-cold sucrose-based artificial cerebral spinal fluid (aCSF) containing (in mM): 180 sucrose, KCl 2.5, MgSO4 10, NaH2PO4 1.25, NaHCO3 25 Glucose 10, CaCl2 0.5, ascorbic acid 1, N-acetyl cysteine 2, tauroine 1, Ethyl pyruvate 20 and saturated with 95% O2 and 5% CO2 at pH 7.3, 300–310 mOsm. Indomethacin (45 µM), aminoaguandine (200 µM) and uric acid (400 µM) were added to improve slice viability (Griffiths et al., 1993; Pakhotin et al., 1997; Proctor, 2008). The brain was quickly removed and placed into the same sucrose-based aCSF. Using a HM-650V Microslicer (Microm GMBH, Germany) sagittal slices were cut at room temperature. Slices were then transferred to an interface holding chamber at room temperature containing oxygenated standard aCSF containing (in mM): NaCl 126, KCl 3, MgSO4 1.6, NaH2PO4 1.25, NaHCO3 26, glucose 10, CaCl2 2 with an osmolality between 300 and 310 mOsm, where they were left for at least 1 h.

2.2. Extracellular recordings

Slices were transferred to an interface recording chamber (Scientific System Design Inc., Canada) at 32–34 °C and continually perfused at 1–2 ml/min with standard aCSF. Local field potential (LFP) recordings were made using borosilicate glass microelectrodes pulled on a Flaming-Brown micropipette puller (P-2000; Sutter Instrument Co., USA) filled with standard aCSF (resistance of 1–3 MΩ). For cross-correlation recordings, electrodes were placed in a single slice (in layers II/III, Va and Vb), in a single vertical column and recorded for at least 20 min. Signals were amplified 1000-fold using an EXT10-2F amplifier and an LHBF-48X filter (NPI Electronics GMBH, Germany), high- and low-pass filtered at 0.5 Hz and 700 Hz respectively. Low amplitude 50 Hz signal interference was removed using a HumBug (Quest Scientific, North Vancouver, Canada). Signals were digitized and recorded at 10 kHz using a CED micro-1401 mkll digitizer and Spike2 software (Cambridge Electronic Design, UK) and saved to disk.

2.3. Drug application

Oscillatory activity was induced through bath application of KA (150 nM) and CCh (10 µM) and left to stabilise for at least 60 min prior to recording. Drugs were bath applied in known concentrations having been previously prepared in stock solutions of 1–50 mM and stored at −20 °C prior to application. The drugs used were carbamoylcholine chloride (carbachol), carbonoxolone, diazepam, zolpidem, atropine (Sigma Ltd., Gillingham, UK), kainic acid, CPPCOET, gabazine, MPEP hydrochloride (Abcam, Cambridge, UK) and CGP58845, LY341495, MK-801, picrotoxin and SYM2206 (Tocris Bioscience, Bristol, UK). All drugs were left for at least 40 min before data was sampled or next dose was applied, with the exception of carbonoxolone which was applied for at least 90 min.

2.4. Data analysis

Data were analysed off-line using Spike2 (CED, UK). Raw data presented were filtered using IIR digital filtering by Bessel band pass between 3 and 10 Hz for theta oscillations and 30–45 Hz for gamma oscillations and were forward and reverse filtered using a custom Matlab script in order to preserve phase information. Some data (presented in Fig. 1A) were filtered using IIR digital filtering by Bessel low-pass at 60 Hz. Time-frequency profiles were generated using a Morlet-wavelet time-frequency analysis over the 0.5–50 Hz range in frequency bins of 0.5 Hz. Cross- and auto-correlation graphs were generated in Spike2 and referenced to the electrode in LVa. These were presented over 0.2 s for theta oscillations and 0.02 s for gamma oscillations. Results were pooled from 6 recordings to provide a mean result ± SEM. Changes to power values were derived from power spectra generated with Fourier analysis on digitized data of 40 s epochs of recorded activity from control
and drug applied conditions. Unless otherwise stated pooled data are represented as mean peak power values normalised to control ± SEM. Statistical analyses performed were Wilcoxon matched-pairs signed rank test for all data except diazepam, gabazine, LY341495 and zolpidem where the Kruskal-Wallis test followed by Dunn’s multiple comparisons test was performed to account for the consecutive concentrations of the drug tested. No significance is signified by “ns”, whilst p < 0.05 is denoted by *, p < 0.01 by ** and p < 0.001 by ***. Significant changes in power and frequency are given in a summary table (Table 1) with changes denoted by arrows (up represents increased frequency or power and down shows decrease. Number of arrows corresponds to significance at 1, 2 or 3*).

2.5. Modulation index (MI) and peak-triggered average analysis

Modulation index analyses were performed in Matlab (R2015b) by MathWorks. Analyses presented in Fig. 2 were performed on
control data epochs that correspond to those used in subsequent figures and analyses. Measurement of Phase-amplitude coupling (PAC) to determine the modulation index of theta and gamma oscillations were performed using purpose built scripts previously described in Tort et al. (2010). Modulation index is presented as the mean ± SEM. In order to ensure robustness a high frequency peak-triggered average of the LFP was also constructed using a Matlab script supplied by B Polletta, based on the work of López-Azcárate et al. (2013). We set a threshold of MI > 0.0001 as evidence of coupling, and coupling was found in around 75% of slices tested.

### Table 1

Summary of theta-gamma frequency and power changes in response to various ligands.

<table>
<thead>
<tr>
<th>Drug</th>
<th>N (Slice)</th>
<th>Theta Frequency</th>
<th>Gamma Frequency</th>
<th>Theta Power</th>
<th>Gamma Power</th>
</tr>
</thead>
<tbody>
<tr>
<td>GABAergic receptors</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gabazine 250 nM</td>
<td>7</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zolpidem 10 nM</td>
<td>14</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GABAergic receptors</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Picrotoxin 50 µM</td>
<td>8</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diazepam 30 µM</td>
<td>8</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zolpidem 10 nM</td>
<td>14</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CGP55845 5 µM</td>
<td>17</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GABAergic receptors</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Picrotoxin 50 µM</td>
<td>8</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diazepam 30 µM</td>
<td>8</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zolpidem 10 nM</td>
<td>14</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CGP55845 5 µM</td>
<td>17</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ionotropic glutamate receptors</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SYM 2006 20 µM</td>
<td>20</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MK-801 20 µM</td>
<td>12</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metabotropic glutamate receptors</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CPCCOEt 20 µM</td>
<td>7</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTEP 100 µM</td>
<td>8</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cholinergic receptors</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atropine 5 µM</td>
<td>7</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gap junctions</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

3. Results

Recording in layer V of M1, application of CCh and KA generated simultaneous rhythms at theta frequency (6.6 ± 0.1 Hz, n = 169) and gamma frequency (36.6 ± 0.4 Hz, n = 169; Fig. 1Ai and Aii). Application of CCh (10 µM) resulted in a significant increase in neuronal activity at theta frequency (control mean peak power 2.50 ± 0.61 µV² versus 10.14 ± 2.43 µV² in CCh; n = 11, p < 0.05; Fig. 1B–D) and gamma frequency (control mean peak power 0.54 ± 0.13 µV² versus 1.89 ± 0.43 µV² in CCh; n = 11, p < 0.05; Fig. 1B–D). Subsequent addition of KA (150 nM) significantly increased the neuronal activity resulting in continuous oscillatory activity in the theta (mean peak power 23.48 ± 5.16 µV², n = 11, p < 0.001 compared to control; Fig. 1B–D) and gamma (22.17 ± 5.71 µV², n = 11, p < 0.001 compared to control; Fig. 1B–D) frequency ranges. Hence, co-application of both KA and CCh was required to reliably produce theta and gamma oscillations and was used for all further experiments. Interestingly, and as shown in the representative power spectrum in Fig. 1C, following addition of both KA and CCh we sometimes noted a peak in the low beta band (13–21 Hz) and a shift in peak theta frequency towards higher values. The latter

![Fig. 2. Topography of theta-gamma oscillations across layers of M1.](image_url)

Frequency (i) and power (ii) of (A) theta and (B) gamma oscillations from the superficial (layer II/III) to the deep (layer Vb) layers and (iii) cross-correlations demonstrating the lag time between layers.
effect was suggestive of development of a theta rhythm after application of KA that was in addition to the existing CCh-induced theta oscillation.

Previous work in our laboratory (Yamawaki et al., 2008) showed that the amplitude of beta oscillatory activity was greatest in deep layers of M1 and we next investigated the power of theta and gamma activity across cortical layers. On moving the recording electrode stepwise down from the pial surface of M1 towards the striatum, we found the power of both theta (Fig. 2Ai-ii) and gamma activity (Fig. 2Bi-ii) to be greatest in upper layer V. Hence, mean peak power for theta activity was 22.66 ± 3.03 µV² in layer II/III, compared to 61.49 ± 3.01 µV²/Hz in layer Va and 15.85 ± 2.52 µV² in layer Vb (n = 6, p < 0.01, ANOVA). Similarly, for gamma activity mean peak power was 22.27 ± 5.01 µV² in layer II/III, compared to 51.52 ± 3.59 µV² in layer Va and 26.21 ± 5.85 µV² in layer Vb (n = 6, p < 0.05, ANOVA). However, cross-correlation analysis revealed a more complex relationship between oscillatory activity in different layers. As can be seen in Fig. 2Aii, theta activity in deep M1 (layer Vb) lagged similar activity in layer Va (average lag 5 ms), as did activity in superficial M1 (average lag 6 ms). In both cases, correlation coefficients were low (LII/III versus LVa - 0.2164 ± 0.07 and LVb versus LVa - 0.11 ± 0.04). By contrast, in the case of gamma oscillations, the waveform in layer Va led layer Vb by an average of 4 ms and lagged superficial layers II/III by 3 ms. Correlation was much stronger across layers (LII/III versus LVa - 0.38 ± 0.05 and LVb versus LVa - 0.29 ± 0.07). To further explore and understand the data we next investigated whether any interaction between the two rhythms could be detected.

The theta-gamma activity present in our in vitro preparation was the first such simultaneous persistent activity we have observed in this brain slice preparation, however, cross-frequency coupling has been shown many times in vivo. In order to confirm the existence of cross-frequency coupling in our data, we subjected time series data to further analyses. Recordings were analysed using the modulation index, based on the method of Tort et al. (2010), which offers a means of detecting PAC. The Tort et al. approach calculates how much an empirical amplitude distribution deviates from an ideal distribution and produces a numerical output (the modulation index) which is a measure of the intensity of phase coupling. Although some recordings 14/54 slices (26%) showed no coupling above our threshold for detection (see methods), in many cases we were able to determine that theta-gamma oscillations in M1 were coupled (Fig. 3A-C; modulation index 2.28 × 10⁻² ± 4.67 × 10⁻³, n = 8). Similarly, we used the peak of the gamma oscillation waveform to trigger averaging of the theta oscillatory activity (Lopez-Azcarate et al., 2013; see methods), and this confirmed that packets of gamma activity were associated with the peak of the theta wave (Fig. 3D).

These analyses suggested that theta and gamma activity were coupled, and in order to provide further evidence of gamma and theta oscillations arising from separate neuronal networks a pharmacological dissection of mechanisms underlying the two oscillations was undertaken.

3.1. GABA receptor modulation of theta-gamma activity

Previous studies have shown that the oscillations in M1 are dependent on phasic GABAA receptor mediated inhibition (Yamawaki et al., 2008). Similarly, gamma oscillations have been shown to be exquisitely sensitive to blockade of GABAA receptor mediated inhibition by low concentrations of the competitive GABAA receptor antagonist, gabazine (250 nM). We tested gabazine at low (250 nM) and high (2 µM) concentration (Roopun et al., 2006) (Fig. 4A). At 250 nM gabazine significantly increased the power of theta oscillations (147.9± 10.2% of control, n = 7, p < 0.05) while 2 µM gabazine shows an additional effect increasing the power by 181.0± 11.6% of control, n = 7, p < 0.001 (Fig. 4Ai, iii, iv). Both 250 nM and 2 µM gabazine substantially decreased the power of gamma oscillations (250 nM: 32.3± 4.9% of control, n = 16, p < 0.001; 2 µM: 27.5± 7.5% of control, n = 7, p < 0.01; Fig. 4Aii, iii, iv), indicating high sensitivity as previously reported for neocortical gamma activity. The effect of blocking GABAA receptors was confirmed using picrotoxin (Fig. 4B), which blocks the GABAA receptor ionophore. The application of 50 µM picrotoxin caused a similar decrease in gamma oscillatory power as seen with gabazine (28.3± 7.4% of control, n = 8, p < 0.01; Fig. 4Biv) and a significant increase in the power of theta oscillations (239.8± 61.5% of control, n = 8, p < 0.01; Fig. 4B i-iv).

We have previously shown that beta frequency oscillatory activity in M1 is sensitive to ligands which bind at the benzodiazepine site of the GABAA receptor, and we next explored the actions of benzodiazepine site ligands on theta and gamma activity. The benzodiazepine site agonist, diazepam, was initially applied at a concentration of 30 nM but there was no significant change in the power of theta or gamma oscillations at this concentration (theta: 174.0± 43.5% of control, n = 8, ns; gamma: 121.9± 12.5% of control, n = 8, ns; Fig. 5A). However at a concentration of 100 nM diazepam resulted in a significant increase in the power of both theta (188.8± 26.1% of control, n = 8, p < 0.05; Fig. 5Ai, iii, iv) and gamma oscillations (142.2± 22.3% of control, n = 8, p < 0.05; Fig. 5Aii, iii, iv). Zolpidem is a non-benzodiazepine hypnotic which is specific for GABAergic receptors containing the z1 subunit at concentrations up to 400 nM (Crestani et al., 2000). When zolpidem was applied to theta oscillations there was no significant change at 10 and 30 nM concentrations (10 nM: 119.1± 6.0% of control, n = 14, ns; 30 nM: 126.4± 10.1% of control, n = 14, ns; Fig. 5Bi, iii, iv). However, increasing the concentration to 100 nM did result in a significant increase in power (160.7± 16.0% of control, n = 8, p < 0.001). In contrast, gamma oscillations increased in power upon addition of zolpidem, at all concentrations tested (10 nM: 148.5± 10.1% of control, n = 14, p < 0.05; 30 nM: 871.4± 14.4%, n = 14, p < 0.001: 100 nM: 276.3± 28.0% of control, n = 8, p < 0.001; Fig. 5Bii, iii, iv).

Finally, we investigated the involvement of GABAB receptor mediated inhibition in theta and gamma oscillations using the GABAB receptor antagonist, CGP55845, at 5 µM. Unlike the differing effects of the GABAA receptor antagonists, both theta and gamma oscillations showed significant increases in power in 5 µM CGP55845. Theta oscillations increased in power to 131.8± 10.6% of control (n = 17, p < 0.01, Fig. 6Ai and B and C) and gamma oscillations increased in power to 149.4± 10.9% of control (n = 17, p < 0.001, Fig. 6Aii, B and C). Application of CGP55845 also resulted in significant increases in both theta and gamma oscillatory frequencies (theta: to 119.1± 8.7% of control, n = 17, p < 0.01; gamma: to 133.5± 10.3% of control, n = 17, p < 0.01, data not shown).

3.2. Glutamate receptor modulation of theta-gamma activity

We next determined the role of excitatory glutamatergic transmission on coupled theta and gamma activity. Firstly, the role of AMPA receptors in the generation of theta and gamma oscillations was assessed using the antagonist SYM2206. SYM2206 (20 µM) significantly increased the power of the theta oscillations (333.8± 20.2% of control, n = 20, p < 0.001; Fig. 7Ai, iii, iv). In contrast, as with the blockade of GABAA receptors, SYM2206 (20 µM) dramatically decreased the power of gamma oscillations (20.2± 3.2% of control, n = 20, p < 0.001; Fig. 7Aii, iii, iv). It seems likely that the decrease in gamma activity and the increase in theta power are entirely separate mechanisms, however, it may be that SYM2206 merely depresses gamma frequency to the point where it is slow enough to contribute to an apparent increase in theta
To investigate this, we measured the time course (data not shown) of the effects of SYM2206 on theta and gamma activity and it was notable that theta power peaked about 15 min prior to maximal depression of gamma activity, suggesting mechanistic independence. To assess the contribution of NMDA receptors we used the NMDA receptor non-competitive antagonist, ketamine, (20 μM), which increased theta to 146.6± 9.2% of control, n = 7, p < 0.05 and gamma: to 201.2± 23.6% of control, n = 7, p < 0.05, data not shown). Since ketamine may have non-NMDA receptor actions, we confirmed these data using another non-competitive NMDAR antagonist, MK-801. Application of MK-801 (20 μM) resulted in significant increases in both theta and gamma oscillations (theta: 201.3± 22.5% of control, n = 12, p < 0.001; gamma: 254.7± 36.5% of control, n = 12, p < 0.001; Fig. 7Bi-iv). When we applied competitive NMDAR antagonists, we found gamma, but not theta activity to be augmented. Hence, when we applied 2-AP5 at 50 μM theta oscillations showed no significant change and gamma power was enhanced to 166.3± 13.6% of control, (n = 15, p < 0.001, data not shown) and similar experiments using the high affinity antagonist CPP (5 μM) again showed no significant change to theta power and increased gamma oscillatory power (179.5± 15.2% of control, n = 11, p < 0.01, data not shown).

![Fig. 3. Phase amplitude cross-frequency coupling and spike-triggered average analysis.](image)

(A) Average phase angle representations of recordings (i) demonstrating theta-gamma PAC and (ii) those not demonstrating theta-gamma PAC. (B) Comodulogram demonstrating frequency pairs showing PAC (denoted by white arrow) | (C) Bar graph demonstrating significant difference in modulation index (MI) between recordings showing PAC (+) and those not (−). (D) Representative spike-triggered average demonstrating gamma frequency oscillation at the peak of theta oscillation. ***, p < 0.001.
Fig. 4. GABA<sub>A</sub> receptor block increases theta oscillatory power whilst decreasing gamma oscillatory power.

(A) Effects of GABA<sub>A</sub> receptor antagonist gabazine (250 nM and 2 μM) on (i) theta and (ii) gamma oscillations. (iii) Representative power spectra showing peak power before (solid line) and after 250 nM (dashed line) and 2 μM (dotted line) gabazine. (iv) Bar graphs showing peak oscillatory power of theta (grey bars) and gamma (red bars) oscillations normalised to control. 

(B) Effect of the GABA<sub>A</sub> receptor channel blocker picrotoxin (50 μM) on (i) theta and (ii) gamma oscillations. (iii) Representative power spectra demonstrating peak responses before (solid line) and after picrotoxin (dashed line). (iv) Bar graphs showing peak oscillatory power of theta (grey bars) and gamma (red bars) oscillations normalised to control. *p < 0.05 **p < 0.01, ***p < 0.001. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Fig. 5. Differential actions of benzodiazepine site modulation.

(A) Effects of diazepam (30 and 100 nM) on (i) theta and (ii) gamma oscillations (iii) Representative power spectra showing peak responses before (solid line) and after application of 30 nM (dashed line) and 100 nM (dotted line) diazepam. (iv) Bar graphs showing peak oscillatory power of theta (grey bars) and gamma (red bars) oscillations normalised to control. 

(B) Effects of zolpidem (10, 30 and 100 nM) on (i) theta and (ii) gamma oscillations (iii) Representative power spectra demonstrating peak responses before (solid line) and after application of 10 nM (dashed line), 30 nM (dotted line) and 100 nM (hybrid line) zolpidem. (iv) Bar graphs showing peak oscillatory power of theta (grey bars) and gamma (red bars) oscillations normalised to control. *p < 0.05 **p < 0.01 ***p < 0.001. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
It is well established that activation of mGluRs may induce oscillatory activity in vitro (Whittington et al., 1995), and we next investigated the effect of antagonists for each of the group I mGluR subtypes to assess their involvement in theta and gamma oscillations in M1. We first blocked mGluR1 receptors with the non-competitive antagonist CPCCOEt. Application of CPCCOEt (20 μM) resulted in a significant increase in the power of both the theta and gamma oscillations (theta: 184.3 ± 22.5% of control, n = 7, p < 0.05; gamma: 216.1 ± 22.4% of control, n = 7, p < 0.05; Fig. 8A). When we applied MTEP (20 μM) in order to block mGluR5 receptors, again this resulted in a significant increase in the power of both the theta and gamma oscillations such that theta power increased to 168.4 ± 18.5% of control, n = 8, p < 0.01 and gamma to 163.7 ± 10.8% of control, n = 8, p < 0.01 (Fig. 8B). By contrast, activation of group I mGluRs with the non-selective agonist, DHPG depressed theta power and had no significant effects on gamma activity (DHPG theta = 79.9 ± 4.0% of control, n = 10, p < 0.01 gamma = 89.6 ± 7.1% of control, n = 10, ns, data not shown).

3.3. Effects of other ligands on theta-gamma activity

Carbenoxolone has been used extensively to block gap junctions and has previously been shown to abolish beta oscillations in M1 (Yamawaki et al., 2008). Application of carbenoxolone (200 μM) for 90 min resulted in a significant decrease of both theta and gamma oscillatory power (theta: 40.6 ± 5.1% of control, n = 13, p < 0.001; gamma: 28.7 ± 5.7% of control, n = 13, p < 0.001; Fig. 9A). The involvement of muscarinic acetylcholine receptors (mAChR) in both theta and gamma oscillations has been shown in vivo and through the use of CCh to induce oscillations in slices (Konopacki et al., 1987; Buhl et al., 1998; Fisahn et al., 1998; Lukatch and MacIver, 1997). Application of atropine (5 μM) completely abolished both theta (24.9 ± 9.0% of control, n = 7, p < 0.05, Fig. 9B) and gamma (9.1 ± 3.3% of control, n = 7, p < 0.05, Fig. 9B) oscillations.

4. Discussion

Using a modified slice preparation technique to enhance slice viability we have been able to generate simultaneous theta and gamma oscillations in sagittal slices of adult rat M1 using a pharmacological approach. These two rhythms are superficially similar to ‘mu’ and gamma activity we have reported in M1 in vivo using magnetoencephalography in human brain (MEG; Ronnqvist et al., 2013), although it is true to say that ‘natural’ M1 activity rarely has the power, or the sharply defined peaks seen in the in vitro brain slice. Presumably this reflects the difference between movement-elicited transient oscillatory activity in vivo and the strongly driven, persistent activity in vitro. The oscillations we report here show greatest power in layer V and appear to display cross-frequency coupling. M1 theta and gamma oscillations are
Fig. 7. AMPA receptor block increases theta power whilst reducing gamma power, whilst NMDA receptor block increased both theta and gamma oscillatory power.

(A) Effect of AMPA receptor antagonist SYM2206 (20 μM) on (i) theta and (ii) gamma oscillations (iii) Representative power spectra showing peak responses before (solid line) and after (dashed line) application of SYM2206. (iv) Bar graphs showing peak oscillatory power of theta (grey bars) and gamma (red bars) oscillations normalised to control. *p < 0.05 **p < 0.01, ***p < 0.001. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

(B) Effect of the non-competitive NMDA receptor antagonist MK-801 (20 μM) on (i) theta and (ii) gamma oscillations. (iii) Representative power spectra demonstrating peak responses before (solid line) and after (dashed line) application of 20 μM MK-801. (iv) Bar graphs showing peak oscillatory power of theta (grey bars) and gamma (red bars) oscillations normalised to control. *p < 0.05 **p < 0.01, ***p < 0.001.
Fig. 8. Blocking group I metabotropic glutamate receptors increases the power of theta and gamma oscillations in layer V of M1.

(A) Effect of the mGluR1 antagonist CPCCOEt (20 μM) on (i) theta and (ii) gamma oscillations. (iii) Representative power spectra showing peak responses before (solid line) and after (dashed line) application of CPCCOEt. (iv) Bar graphs showing peak oscillatory power of theta (grey bars) and gamma (red bars) oscillations normalised to control. (B) Effect of mGluR5 antagonist MTEP (100 nM) on (i) theta and (ii) gamma oscillations (iii) Representative power spectra demonstrating peak responses before (solid line) and after (dashed line) application of MTEP. (iv) Bar graphs showing peak oscillatory power of theta (grey bars) and gamma (red bars) oscillations normalised to control. *p < 0.05 **p < 0.01, ***p < 0.001. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Fig. 9. Block of gap junctions and muscarinic acetylcholine receptors decreases power of theta and gamma oscillations.

(A) Effects of the gap junction blocker, carbenoxolone, (200 μM) on (i) theta and (ii) gamma oscillations. (iii) Associated power spectra demonstrating peak responses before (solid line) and after (dashed line) application of carbenoxolone. (iv) Bar graphs showing peak oscillatory power of theta (grey bars) and gamma (red bars) oscillations normalised to control.

(B) Effects of the mACh receptor blocker atropine (5 μM) on (i) theta and (ii) gamma oscillations. (iii) Associated power spectra demonstrating peak responses before (solid line) and after (dashed line) application of atropine. (iv) Bar graphs showing peak oscillatory power of theta (grey bars) and gamma (red bars) oscillations normalised to control. *p < 0.05  **p < 0.01  ***p < 0.001. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
generated by discrete mechanisms, responding differentially to a range of pharmacological interventions at the major CNS excitatory and inhibitory receptors. Consistent with previous reports in cortex (e.g. Roopun et al., 2006), gamma activity was excessively sensitive to blockade of fast synaptic inhibition, but was also sensitive to gap junction block. Theta activity was much less sensitive to modulation of fast synaptic inhibition and excitation, suggesting a greater reliance on non-synaptic mechanisms. Further study of dual theta-gamma activity in the in vitro slice preparation has the potential to allow greater mechanistic understanding of how phase-amplitude coupling is mediated at the cellular and local network level, and how it is modulated by pharmacological manipulation.

4.1. KA and CCh generate simultaneous theta and gamma oscillations in layer V M1 in vitro

Co-application of KA and CCh has been used to generate gamma oscillations in vitro in hippocampus (Fisahn et al., 1998), somatosensory cortex (Buhl et al., 1998; Roopun et al., 2006) and entorhinal cortex (Cunningham et al., 2003). We have previously used higher concentrations of KA and CCh (400 nM and 50 μM respectively) to generate beta oscillations in M1 (Yamawaki et al., 2008). However, in the present studies we have found that lower concentrations (100–150 nM KA and 5–10 μM CCh), are capable of producing multiple rhythms.

In relation to the novel observation of dual rhythms, we suspect that these differences are due to the improved viability of our M1 slice, and probably reflect better preservation of the GABA interneurons required for rhythmogenesis. As detailed in the Methods section above, we have utilised a number of ‘neuroprotectant’ agents during slice preparation, namely NAC, aminoguanidine, taurine, ethyl pyruvate and ascorbate, and these agents provided a step-change in slice viability and successful production of neuronal network oscillations in deep M1. When we performed immunocytochemistry for common interneuronal proteins such as parvalbumin (PV), calbindin and somatostatin, we did not observe a significant change in preservation of inhibitory cell somata compared to standard aCSF (data not shown), but we did see evidence of better dendritic preservation, though this is hard to quantify.

NAC has been shown to have neuroprotectant actions, restoring mitochondrial function in traumatic brain injury (Xiong et al., 1999) and increasing the pool of glutathione, a reactive oxygen species (ROS) scavenger (Chen et al., 2008; Ferrari et al., 1995). Aminoguanidine is a ROS scavenger associated with preventing apoptosis after ischemia (Dawson et al., 1993; Hunot et al., 1996; Sun et al., 2010). Taurine, a modulator of cytosolic and intra-mitochondrial calcium concentrations, can be employed to prevent mitochondrial death, and thus cell death, during traumatic events (Ellen and Lehmann, 1989). Similarly, cell volume regulation is a vital process (Inoue et al., 2005) and is regulated in part by taurine (Beetsch and Olson, 1998). Ascorbic acid, an important antioxidant and neuro-modulator is found at its highest concentration in the brain (Rice, 2000). It is found in CSF and extracellular fluid and is taken up by neurons where it is found at its highest concentration at 10 mM. Providing ascorbic acid in the modified aCSF means it can directly scavenge ROS and can be hetero-exchanged with glutamate, increasing levels in the extracellular fluid to minimise excitotoxicity. The standard aCSF solution used pyruvate in its salt form (sodium pyruvate). However, sodium pyruvate has been shown to be unstable and to dimerize rapidly into pyruvate hydrate and subsequently more slowly into parapyruvate, a compound that may have a synaptic component as well as the previously discussed non-synaptic element and this may explain the shift in peak theta frequency seen between addition of CCh and subsequent addition of KA. The effects of benzodiazepine site agonists are suggestive of an increase in oscillatory power following recruitment and synchronous activation of pyramidal neurons, and may be related to the enhanced beta activity or ‘beta buzz’ seen in vivo (Glaze, 1990).

Recent evidence suggests that a sustained inhibitory membrane conductance ($\Delta I_{\text{homo}}$), arising from spill over of GABA, and mediated by high affinity extrasynaptic GABA$_A$ receptors (Bright et al., 2007; Farrant and Nusser, 2005) also plays a fundamental role in shaping network excitability (Mann and Mody, 2010; Semyanov et al., 2004) and this current is also present in M1, playing a role in beta oscillatory activity (Prokic et al., 2015).

Blockade of NMDA receptors with NMDAR antagonists significantly increased power in both the theta and gamma band in M1, consistent with other reports of such NMDAR antagonist effects in the literature (Hakami et al., 2009; McNally et al., 2011; Pinault, 2008). It has been reported that GABA interneurons in hippocampal CA1 are highly sensitive to NMDAR antagonism (Grunze et al., 1996), and selective genetic ablation of NMDAR on parvalbumin positive (PV$^+$) interneurons has been shown to augment gamma activity in the same region (Korotkova et al., 2010), with disinhibition of GABA interneurons being suggested as a mechanism for augmented excitability in pyramidal neurons, leading to increased oscillatory power. In the same study, Korotkova et al. (2010) showed selective interneuronal NMDAR ablation reduced theta power in CA1, an effect not seen in M1. This may reflect different local circuit organisation between hippocampus and neocortex, or simply be due to the acute versus chronic effects of ablation as compared to pharmacological intervention. Interestingly, the competitive antagonists, CPP and 2-AP5 did not affect theta power in our experiments, suggesting that NMDAR on GABA interneurons responsible for theta generation are not blocked at the concentrations used. The augmentation of theta power in hippocampus by NMDA antagonists contrasts with previous reports of theta power
4.3. Gap junctions are required for both theta and gamma oscillations

Networks of inhibitory interneurons are known to be connected together by gap junctions, which allow them to provide large synchronous IPSPs to local excitatory cells involved in oscillations (Deans et al., 2001; Galarrreta and Hestrin, 1999; Gibson et al., 1999). Pharmacological blockade of gap junction function with carbamoylcholine, has been shown to abolish ultrafast oscillations (80–200 Hz, Draguhn et al., 1998) and gamma/beta oscillation in vitro (Cunningham et al., 2003; Deans et al., 2001; Roopun et al., 2006; Traub et al., 2000). Consistent with these observations, application of carbamoylcholine, a gap junction channel blocker, here decreased and abolished theta and gamma oscillations respectively, confirming the essential nature of the inhibitory input provided by the interneuronal network.

4.4. mGluR mediated modulation of theta and gamma oscillations

Activation of mGluRs has in the past been shown to elicit gamma oscillations in hippocampus and neocortical slices via networks of interneurons (Whittington et al., 1995), reflecting the increase in network excitability seen in response to group I mGluR activation. Here we show that the addition of antagonists of group I mGluRs results in increased theta and gamma oscillatory power. Previous studies have reported that activation of group I mGluRs decreased synaptic inhibition (Desai and Conn, 1991; Varma et al., 2001) and it seems likely that blockade of mGluRs may result in increased synaptic inhibition, either through reduction in constitutive activity at the receptor or through reduction of glutamate driven activation of mGluRs in the KA/CCh activated network. In such a scenario, increased action-potential dependent GABA release may lead to increased oscillatory power in the same manner that positive modulation of GABA_A receptors with benzodiazepines or barbiturates are known to do.

4.5. Theta-gamma cross-frequency coupling in M1

CFC (which includes PAC as well as many other forms of coupling) aids inter-network computational processing and communication and has been identified in behaving rats (Bragin et al., 1995; Buzsáki and Chrobak, 1995; Quilichini et al., 2010), monkeys (Lakatos et al., 2005) and in man (Mormann et al., 2005). CFC manifests between multiple brain regions in response to sensory inputs and cognitive or motor tasks and, as such, CFC is believed to be the primary mechanism by which brain areas and neuronal networks spatially and temporally co-ordinate activity (Gray et al., 1989; Jensen and Colgin, 2007). Igarashi et al. (2013) demonstrated the importance of theta and gamma oscillatory CFC in the sensorimotor area in vivo, suggesting that coupling between different ranges of gamma oscillations (high and low) was a dynamic system which could be attributed to different movement and behavioural states. To date, reports of CFC have been based on recordings made in vivo (Bragin et al., 1995; Chrobak and Buzsáki, 1998; Csicsvari et al., 2003; Mormann et al., 2005; Quilichini et al., 2010; Tort et al., 2008), and the current report is, to our knowledge, the first demonstration of CFC in an in vitro preparation of primary motor cortex.

Many studies have reported the importance of interneurons in generating synchronised IPSPs/IPSIs that contribute to the generation of gamma oscillations (e.g. Traub et al., 1996; Whittington et al., 1995). Similarly, mechanistic investigations in mouse hippocampal area CA1 in vivo, have shown specifically that coupling (and not simply amplitude) of theta-gamma oscillations requires intact GABA inhibition onto PV + interneurons (Wulff et al., 2009). The coupled oscillatory activity we have reported here suggests that the relevant inhibitory networks in the M1 slice remain intact and that this preparation may prove useful for further mechanistic study of CFC in vitro.

5. Conclusions

These data show simultaneous theta and gamma oscillatory activity in layer V of M1 shows cross-frequency coupling and that the coupled rhythms are generated by different mechanisms.

Acknowledgements

This work was supported by funding from a BBSRC CASE-Studentship with Eli Lilly (NWJ). KAW and MJO are employees of Eli Lilly & Co. Ltd. MO was supported by The Scientific and Technological Research Council of Turkey (TUBITAK). The authors have no conflicts of interest to declare.

References

activity of inhibitory networks in neocortex requires electrical synapses containing
Desai, M.A., Conn, P.J., 2011. Excitatory effects of ACPD receptor activation in the
hippocampus are mediated by direct effects on pyramidal cells and blockade of
by electrical synchronization of cortical networks in the rat entorhinal cortex. J.
Neurosci. 20, 7846–7854.
Ellen, K., Lehmann, A., 1989. Calcium dependency of N-methyl-D-aspartate toxicity in
slices from the immature rat hippocampus. Neuroscience 32, 371–379.
connected by electrical synapses. Nature 402, 72–75.
Gibson, J.R., Beierlein, M., Connors, B.W., 1999. Two networks of electrically
driven inhibitory neurons in neocortex. Nature 402, 75–79.
Gillies, M.J., Traub, R.D., LeBeau, F.E.N., Davies, C.H., Gloveli, T., Buhl, E.H.,
Whittington, M.A., 2002. A model of a tetrode-resistant theta oscillations in
rat hippocampal area CA1. J. Physiol. 543, 779–793.
Gray, C.M., 1994. Synchronous oscillations in neuronal systems: mechanisms and
cortex exhibit inter-columnar synchronization which reflects global stimulus
Griffiths, M.J.D., Messent, M., Macalister, R.J., Evans, T.W., 1993. Aminoquinidine
Grunze, H.C., Rainnie, D.G., Hasselmo, M.E., Barkai, E., Hearn, E.F., McCarley, R.W.,
Griswold, W.R., 1995. Phase/amplitude reset and theta-gamma interaction in the
human temporal lobe during a continuous word recognition memory task. Hippocampus 15, 890, 90.
O’Keefe, J., Recce, M.L., 1993. Phase relationship between hippocampal place units and
Pakhitov, PL, Pakhikova, I.D., Andreev, A.A., 1997. Functional stability of hippo-
campus slices after treatment with cyclohexylamine inhibitors. Neuroreport 8, 1755–1759.
Pálhalmi, J., Paulsen, O., Freund, T.F., Hajas, N., 2004 Sep. Distinct properties of
temporal patterns of beta desynchronisation and gamma synchronization in
Prokic, E.J., Westay, C., Yamawaki, N., Hall, S.D., Jones, R.S., Stanford, I.M., Ladds, G.,
Woodhall, G.L., 2015. Cortical oscillatory dynamics and benzodiazepine-site modulation of
tonic inhibition in fast spiking interneurons. Neuropharma-
colgy 95, 192–205.
Quilichini, P., Sirota, A., Buzáski, G., 2010. Intrinsically circuit organization and theta-
7, 133.
Roopun, A.K., Middleton, S.J., Cunningham, M.O., LeBeau, F.E.N., Bibbig, A.,
Whittington, M.A., Traub, R.D., 2006. A beta2- frequency (20-30 Hz) oscillation in
103, 15646–15650.
Semanov, A., Walker, M.C., Killmann, D.M., 2004. Tonically active GABA A re-
ceptors; modulating gain and maintaining the tone. Trends Neurosci. 27, 260–262.
ethyl pyruvate solution ameliorates ischemia/reperfusion-induced in-
Entorhinal cortex neurogenesis and gamma oscillations via the hippo-
involve reduced the activation of calpain and caspase-3 in a rat model of stroke.
Neurochem. Int. 56, 634–641.
Szabadics, J., Lorincz, A., Tamas, G., 2001. δ and γ frequency synchronization by
dendritic gabacergic synapses and gap junctions in a network of cortical in-
Tort, A.B.L., Kramer, M.A., Thorn, C., Gibson, D.J., Kubota, Y., Graybiel, A.M.,
Koppell, NJ., 2008. Dynamic cross-frequency couplings of local field potential oscillations
Tort, A.B.L., Komorowski, R., Eichenbaum, H., Koppell, N., 2010. Measuring phase-
amplitude coupling between neuronal oscillations of different frequencies.
A model of gamma-frequency network oscillations induced in the rat CA3 re-
Varma, N., Carlson, G.C., Ledent, C., Alger, B.E., 2001. Metabotropic glutamate re-
ceptors drive the endocannabinoid system in hippocampus. J. Neurosci. 21, RC188.
Wang, X.-J., Buzaki, G., 1996. Gamma oscillation by synaptic inhibition in a hip-

N.W. Johnson et al. / Neuropharmacology 119 (2017) 141–155

155
interneuron networks driven by metabotropic glutamate-receptor activation. Nature 373, 612–615.